Shares of MAP Pharmaceuticals (NASDAQ: MAPP) skyrocketed today, up nearly 60% on the news that the company was being acquired by its marketing partner Allergan (NYSE: AGN) for the premium of $25 per share. In this video, Motley Fool health-care analyst David Williamson tells us some of the unexpected synergies that Allergan, the company behind Botox, will be looking for in MAP Pharmaceuticals, and why this might be a good fit.
MAP Pharmaceuticals' meteoric rise today.
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid